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AbstrAct
Purpose Tuberculosis (TB) is a leading cause of death 
among people living with HIV in sub-Saharan Africa. 
Several factors influence the efficacy of TB treatment 
by leading to suboptimal drug concentrations and 
subsequently affecting treatment outcome. The aim of this 
cohort is to determine the association between anti-TB 
drug concentrations and TB treatment outcomes.
Participants Patients diagnosed with new pulmonary 
TB at the integrated TB-HIV outpatient clinic in Kampala, 
Uganda, were enrolled into the study and started on first-
line anti-TB treatment.
Findings to date Between April 2013 and April 2015, 
the cohort enrolled 268 patients coinfected with TB/HIV 
; 57.8% are male with a median age of 34 years (IQR 
29–40). The median time between the diagnosis of HIV and 
the diagnosis of TB is 2 months (IQR 0–22.5). The majority 
of the patients are antiretroviral therapy naive (75.4%). Our 
population is severely immunosuppressed with a median 
CD4 cell count at enrolment of 163 cells/µL (IQR 46–298). 
Ninety-nine per cent of the patients had a diagnosis of 
pulmonary TB confirmed by sputum microscopy, Xpert/RIF 
or culture and 203 (75.7%) have completed TB treatment 
with 5099 aliquots of blood collected for pharmacokinetic 
analysis.
Future plans This cohort provides a large database of 
well-characterised patients coinfected with TB/HIV which 
will facilitate the description of the association between 
serum drug concentrations and TB treatment outcomes as 
well as provide a research platform for future substudies 
including evaluation of virological outcomes.
trial registration number NCT01782950; Pre-results.
IntroductIon
HIV infection is a major risk factor for the 
development of active tuberculosis (TB) and 
has been associated with poorer outcomes 
and higher relapse rates worldwide.1
The treatment of TB in patients coin-
fected with HIV poses several challenges and 
a number of factors potentially influence 
the efficacy of anti-TB drugs. These factors 
include side effects of treatment, significant 
drug–drug interactions with antiretroviral 
therapy (ART)2 potentially leading to subop-
timal drug concentrations3 and comorbidities 
or opportunistic infections which can cause 
malabsorption. HIV infection, in addition to 
TB infection itself, might be a possible risk 
factor for poor absorption of anti-TB drugs.4 5
TB remains the leading cause of death 
among persons infected with HIV, especially 
in sub-Saharan Africa. While the vast majority 
of the patients coinfected with TB and HIV 
live in sub-Saharan Africa,6 resources and 
technical capacity to measure drug concen-
trations in this region is limited, if not 
completely unavailable.
Several studies have demonstrated that 
patients with TB have suboptimal concen-
trations of anti-TB drugs in blood. Patients 
with TB/HIV coinfection are known to 
have poor drug absorption which contrib-
utes to the suboptimal concentrations. The 
consequence of this is still unclear. Data 
that characterise the pharmacokinetics of 
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Cohort profile
strengths and limitations of this study
 ► This is a prospective pharmacokinetic study with a 
relatively large sample size.
 ► Pharmacokinetic analysis performed at three 
time points and on three occasions enables us to 
estimate the maximum concentrations better.
 ►  The main limitation of this study is that directly 
observed therapy is only performed on the study 
visit and not throughout the course of tuberculosis 
treatment.
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first-line anti-TB drug concentrations in severely immu-
nosuppressed patients with HIV and its association with 
treatment outcome and toxicities are still limited. Some 
studies demonstrating poor treatment outcomes and slow 
treatment response in patients with suboptimal pyra-
zinamide, rifampicin or isoniazid concentrations while 
other studies show no association between anti-TB drug 
concentrations and treatment outcomes.7–9
We established a clinical cohort of indiviuals coinfected 
with HIV/TB in order to contribute to the characteri-
sation of the association between anti-TB drug concen-
trations over the entire anti-TB treatment period, TB 
treatment outcomes in this population. Our hypothesis 
is that patients coinfected with TB/HIV with suboptimal 
anti-TB drug concentrations have more unfavourable TB 
treatment outcomes compared with those with normal 
concentrations.
The aim of this paper is to describe the establishment 
of this well-characterised cohort of HIV-positive patients 
with confirmed pulmonary TB. In addition, we describe 
the scope and design of the cohort, as well as the profile 
of the enrolled patients.
cohort descrIPtIon
The participants of this cohort were enrolled at the 
Infectious Diseases Institute (IDI), Kampala, Uganda, 
a Makerere University centre of excellence in HIV care 
and treatment10 with currently 8000 active patients, and 
350–400 newly diagnosed TB cases seen annually.
In order to improve outcomes of HIV patients coin-
fected with TB in 2008, an integrated HIV-TB clinic was 
established11; patients diagnosed with TB are attended by 
a dedicated well-trained clinical team providing care for 
both HIV and TB and receive drugs from a separate phar-
macy. Additional data with particular attention to TB care 
are entered in the IDI electronic medical record system.12
study design and procedures
In this context, this study aims to describe the pharmacoki-
netic parameters of anti-TB drugs at different time-points 
over the course of treatment for pulmonary TB, and to 
investigate the association between serum concentrations 
of anti-TB drugs and TB treatment response in individ-
uals coinfected with HIV/TB. The patients enrolled into 
the ‘Study on Outcomes related to TB and HIV drug 
Concentrations in Uganda’ (SOUTH) are followed up as 
a cohort for 5 years after the diagnosis of pulmonary TB. 
This cohort provides a research platform for substudies in 
order to answer diverse research questions.
Subjects were considered eligible for the study if they 
were willing to participate and to comply with the study 
procedures, if they were ≥18 years old, HIV infected and 
diagnosed with proven or highly suspected new pulmo-
nary TB. Patients with extrapulmonary TB were excluded 
because treatment outcome assessed by clearance of 
mycobacteria from sputum by the end of treatment is our 
primary objectives and ascertainment of this would be 
challenging in patients with extrapulmonary TB. Patients 
were also excluded if they are pregnant or are plan-
ning a pregnancy, if they were part of an interventional 
study, had comorbidities that reduced life expectancy to 
less than a year (eg, disseminated Kaposi’s sarcoma and 
other cancers), if they had evidence of decompensated 
liver disease and/or aminotransferases>5x upper limit 
of normal or a glomerular filtration rate (GFR) less than 
50 mL/min. Patients are withdrawn from the study on 
patient request or based on medical judgement of the 
study doctor, if they became pregnant, develop a toxicity 
necessitating change or interruption of TB treatment, 
if the drug sensitivity test (DST) shows resistance to any 
first-line anti-TB drug, if they develop Immune Reconsti-
tution Inflammatory Syndrome in organs other than the 
lungs (eg, tuberculous meningitis) or if their baseline 
culture identifies only mycobacteria other than Mycobac-
teria tuberculosis.
Sample size calculation: In previous studies which 
demonstrated that subtherapeutic pyrazinamide concen-
trations were associated with poor treatment outcome, 
subtherapeutic pyrazinamide concentrations were found 
in 33% of the study population.13 In addition, prior data 
indicate that the failure rate for TB treatment is estimated 
to be 5%. We assumed that 33% of our study population 
will have subtherapeutic pyrazinamide concentrations 
and varied their TB treatment failure rate between 1% 
and 7%. Taking into account a 12.5% non-response 
rate, a sample size of 400 patients will be sufficient for 
us to reject the null hypothesis that the failure rates for 
patients with subtherapeutic concentrations and patients 
with normal concentrations are equal with a type I error 
probability of 0.05 and a power of 80%.
All consecutive patients with newly diagnosed pulmo-
nary TB (proven or highly suspected) were screened 
over a period of 24 months and started on TB treatment 
at enrolment. First-line TB treatment was administered 
according to WHO guidelines,14 consisting of rifampicin, 
isoniazid, pyrazinamide, ethambutol during the first 
8 weeks (intensive phase), followed by rifampicin and 
isoniazid (continuation phase) for 16 weeks (a total of 
24 weeks of TB treatment). Patients with positive sputum 
smears after 8 weeks of treatment received intensive phase 
treatment for an additional 4 weeks (up to week 12) with 
a total duration of 28 weeks of TB treatment. Patients 
were put on an efavirenz-based ART regimen if on first-
line ART and lopinavir or atazanavir (both boosted with 
ritonavir)-based ART regimens if in need of second-line 
treatment. The ART initiation was scheduled at 2 weeks 
after initiation of TB treatment regardless of the CD4 
count in ART-naive patients.
Enrolled patients are followed up for 6 months during 
TB treatment and undergo scheduled study visits at 2, 
8 and 24 weeks of TB treatment or 28 weeks for those 
who were still sputum smear positive at week 8. After 
completing TB treatment, patients are followed up for 
a total of 5 years from enrolment to ascertain long-term 
clinical outcomes.
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At every visit a comprehensive patient history focusing 
on evolution of cure and treatment-associated side 
effects is taken and meticulous physical examination is 
performed.
Anti-TB drug concentrations are measured at week 2, 8 
and 24 or 28 at different time points after witnessed drug 
intake: 1 hour, 2 hours and 4 hours postdosing. Labora-
tory safety tests including a full blood count, liver and 
renal function tests are also performed on these study 
visits. Patients receive a light meal consisting of a boiled 
egg, 250 mL of milk, biscuits and a banana given after 
the 1 hour blood draw. The study physicians are blinded 
regarding drug concentrations until the end of the study 
or in case of treatment failure.
Sputum is collected for microscopy and cultures at 
the baseline visit, week 2, 8, and 24 or 28 where appli-
cable. Patients who receive a prolonged intensive phase 
also have sputum analysis at week 12. DST is performed 
at baseline, week 8, 24 or 28 for sputum culture positive 
samples. Chest X-rays are performed at baseline, week 
8 and week 24. In addition, biological samples (blood 
and sputum isolates) from the baseline visit, week 2, 8, 
12 if applicable, and 24 or 28 are stored for future tests 
including pharmacokinetic analysis.
Safety laboratory tests, CD4 cell count and viral load 
measurements are performed at the Makerere Univer-
sity John Hopkins University (MUJHU) Core Laboratory, 
which is College of American Pathologists (CAP)-certi-
fied; TB sputum microscopy and culture at the Medical 
and Molecular Laboratories—Mycobacteriology Labora-
tory located in Mulago National referral Hospital which is 
also CAP-certified; Xpert MTB/RIF (Cepheid) tests and 
measurement of serum drug concentrations at the IDI 
research translational laboratory.
data collection
Three different data collection tools are used for data 
collection: (1) At IDI comprehensive information is 
collected at enrolment in the programme and during 
follow-up for all patients, for example, social and demo-
graphic information, symptoms of TB and TB outcome 
and drug history. Data are entered in real time at each 
visit by providers into an electronic medical record system 
called Integrated Clinic Enterprise Application (ICEA), 
an in house built system based on Microsoft.NET tech-
nologies.15 This system is used for the entire HIV outpa-
tient clinic at IDI and ensures a high standard of data 
collection. (2) DataFax study case report forms (CRF) 
specially designed for the SOUTH study are used to 
collect study-specific information including time of drug 
and food intake, dose of drugs, information on adverse 
events and adherence information. DataFax is a data 
management system designated to manage paper data 
forms; when the faxed form reaches the DataFax server 
the system reads the data using intelligent character 
recognition and enters the data into the study database. 
In order to avoid double collection of data on the same 
visits, the DataFax CRF does not contain any information 
already collected into ICEA. (3) The drug concentrations 
are entered into an EpiData database by the laboratory 
technician to ensure blinding of providers.
Laboratory results performed in MUJHU Core Labo-
ratory are entered into the laboratory database which is 
automatically downloaded daily into the ICEA database 
using an MS SQL Integration Services package.
MeAsureMents
Variables collected include basic demographic data, clin-
ical history, present clinical information including vital 
signs and body weight, TB diagnostic results, haematolog-
ical and chemistry laboratory results, medications, phar-
macokinetic-related variables, adverse events, missed visits 
and TB treatment outcomes as defined by WHO (cure, 
completed, failure, default, loss to follow-up, death).16 
Details of these variables are presented in table 1.
data quality control
Data quality control procedures are carried out for the 
data collected in the three databases: (1) All the data 
collected into ICEA, as per IDI standard procedures, are 
validated daily by a quality control officer who ensures 
that the data are complete and consistent. (2) All the data 
entered in the DataFax database are retrieved and vali-
dated by a verifier. In addition, the DataFax team gener-
ates weekly reports, which show the follow-up status of 
all patients enrolled and summarise all errors flagged by 
the verifiers. (3) Double entry is made into the EpiData 
database and the duplicate entry is then compared using 
the EpiData designated command; where errors are indi-
cated, the entry is reassessed.
data management and linkage of databases
The integrated SOUTH dataset is housed on the IDI 
server in the MS Excel format. The dataset is managed 
and merged by the study data manager and checked for 
completeness and accuracy every 3 months.
Details of the identifiers from different datasets used 
to link the collected data are available in the additional 
material section (online supplementary appendix). 
Each box displays the unique identifiers used to link the 
different databases, while the numbers in the boxes indi-
cate the linkage ‘step number’.
The dataset are backed up in accordance with the 
existing data backup procedures; only the data manager 
has primary access and rights to manage the dataset to 
allow blinding of the study staff.
drugs
Dosing of anti-TB drugs is done according to WHO 
guidelines using fixed-dose combinations; three tablets 
of RHZE (rifampicin, isoniazid, pyrazinamide and etham-
butol) or HR (isoniazid and rifampicin) are prescribed if 
the patient’s weight was <55 kg, four tablets of RHZE or 
HR if weight was ≥55 kg and five tablets of RHEZ or RH if 
weight was ≥70 kg. All attempts are made to use the same 
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Table 1 Type and description of the variables collected in the Study on Outcomes related to TB and HIV drug Concentrations 
in Uganda study
Type of variable Variables Visit Database
Basic demographics Gender, age, address, phone contact Enrolment ICEA
Epidemiological Tribe, marital status Enrolment ICEA
Clinical history Date and result of HIV-positive result, date of enrolment 
into care, history of kidney and liver disease, herb use, 
smoking and alcohol consumption
Enrolment ICEA
Clinical information Present symptoms and duration (days), physical 
examination
Enrolment, week 2, 8, 24 DataFax
TB diagnostic Sputum microscopy, Xpert MTB/RIF*, culture results, 
chest X-ray features,† drug sensitivity test‡
Enrolment, week 2, 8, 24 DataFax
Other laboratory 
results
Full blood count, liver enzymes, renal function, CD4 
count§, viral load ¶
Week 2, 8, 24 MUJHU lab
Medications ART, TB drugs, ART adherence, anti-TB drugs 
adherence, ART side effects, anti-TB drugs side effects, 
comedications including herbal use
Week 2, 8, 24 ICEA, DataFax
Pharmacokinetic-
related variables
Time of last dose of anti-TB drugs and of last food 
intake, duration of treatment, time, accession number, 
drug concentrations
Week 2, 8, 24 DataFax, 
Pharmacokinetic 
Access database
Adverse events Description, severity, duration, relation to study drug, 
relation to disease, action taken, outcome
At time of occurrence DataFax
Missed visit Phone and home visit tracking attempts, tracking 
outcome, reason for missed visit
At time of occurrence DataFax
Outcomes TB resolution,
Treatment outcome (completed or cured, treatment 
default, treatments failure, death, relapse, lost to follow-
up, other**
At week 24 or at the time 
of outcome occurrence
ICEA, DataFax
*Xpert MTB/RIF only at enrolment.
†Presence or absence of infiltrates, cavities, adenopathy, pleural and pericardial effusion.
‡If positive culture.
§CD4 count only at enrolment and week 24.
¶At enrolment if on ART, at week 24 if not on ART at enrolment.
**Withdrawn from the study, relocated/transferred out, stopped anti-TB treatment for clinical reasons.
ART, antiretroviral treatment; ICEA, Enterprise Clinical Electronic Application; lab, laboratory; MUJHU, Makerere University John Hopkins 
University; TB, tuberculosis.
brand, Strides-Arco, of the anti-TB drugs throughout the 
study, however, due to interruption in supplies, we used 
the Cosmos brand of RH (150/75 mg) from May 2014 for 
5 months and the Svizera Labs brand (150/75 mg) from 
October 2014 onwards. Dissolution studies were done in 
the biochemistry laboratory at the University of Zurich 
(UZH) to ensure consistency in the composition of the 
drugs. Patients who were on protease inhibitors are given 
rifabutin (Mycobutin) 150 mg three times weekly instead 
of rifampicin.
diagnostics
Direct and concentrated sputum microscopy is 
performed with auramine stain, and sputum cultures 
using both Löwenstein-Jensen (LJ) and BACTEC MGIT 
960. In patients who fail to spontaneously provide a 
sputum sample, sputum induction is performed. Initially 
Xpert MTB/RIF (Cepheid) was performed at baseline 
in patients who have two negative sputum smear results; 
however, from June 2014 following a change in WHO and 
IDI guidelines, Xpert MTB/RIF is offered as a first diag-
nostic test in all patients suspected to have TB.
drug concentration measurement
At each time point, 10 mL of serum is collected in BD 
VacutainerRapid Serum Tube, separated by centrifuging 
within 1 hour of the blood draw and stored at −80°C. 
Serum concentrations of rifampicin, ethambutol and 
isoniazid are later measured on site using ultraviolet 
high-performance liquid chromatography (UV-HPLC).
The UZH developed assays for the measurement of 
serum levels of (1) ethambutol, (2) rifampicin/rifab-
utin/moxifloxacin, (3) pyrazinamide/isoniazid (4) ataza-
navir, efavirenz and lopinavir (as single assays) using an 
analyser identical to the one at IDI: a. A Ugandan labo-
ratory technologist was trained at UZH for 2 weeks on 
these methods. Assays were subsequently validated and 
implemented at IDI over a period of 7 months. The phar-
macokinetic results generated by HPLC-UV are entered 
into an Excel spreadsheet and the drug concentration 
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Table 2 No of aliquots of serum collected (by November 
2015)
Visit no
Patients with 
samples 
available
Available 
stored serum 
aliquots per 
visit
Total no of 
serum aliquots 
stored
Week 2 252 9 2268
Week 8 227 9 2043
Week 12 35 9 315
Week 24 153 9 1377
Figure 1 Follow-up status of the cohort. Number of patients who were screened, enrolled, withdrawn and followed up. 
*Patients were on protease inhibitor-based antiretroviral therapy. GFR, glomerular filtration rate; TB, tuberculosis.
is calculated for each sample using manual calibration 
curve.
We collect three blood samples per study visit, and each 
sample is divided into three aliquots of up to 1 mL each, 
and are used for pharmacokinetic analysis for the various 
anti-TB drugs (nine aliquots per study visit). Table 2 below 
shows the number of patients with available aliquots for 
pharmacokinetic analysis of anti-TB drugs by November 
2015. The laboratory technician has so far run 5099/6003 
(85%) pharmacokinetic assays on stored blood aliquots, 
1999 for isoniazid and pyrazinamide, 2001 for rifampicin 
and 1099 for ethambutol.
cohort characteristics
From May 2013 to April 2015, a total of 294 patients were 
screened, of which 26 were excluded from the study. 
The main reasons for exclusions were having a history of 
TB (nine patients), four had only extrapulmonary TB, 
three had a GFR<50 mL/min; other reasons are shown 
in figure 1.
A total of 268 patients have been enrolled in the study, 
of which 71 were enrolled in the first calendar year, 140 
in the second calendar year and 57 in the last calendar 
year (figure 2).
The majority of the patients are male (57.8%), the 
median age is 34 (IQR 29–40). The median time between 
the diagnosis of HIV and the diagnosis of TB is 2 months 
(IQR 0–22.5). The majority of the patients are ART naive 
(75.4%). The median CD4 cell count at enrolment is 
163 cells/µL (IQR 46–298) with 57.5% having a CD4 cell 
count <200 cells/µL. All patients have had at least one 
index symptom for TB, with the vast majority (258, 97%) 
reporting cough for at least 2 weeks.
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Figure 2 Number of patients enrolled each quarter. Number of patients enrolled in each year from year 1 to year 3.
Other detailed demographic, epidemiological charac-
teristics are shown in table 3.
Figure 1 also shows the follow-up status of the 268 
patients enrolled. Seventeen (6.3%) died, 3 (1.1%) had 
a positive sputum smear after 5 months of treatment 
and therefore defined as TB treatment failure, 2 (0.7%) 
defaulted from TB treatment, 13 (4.9%) were transferred 
to other public facilities in Kampala on patient’s request, 8 
(3%) were lost to follow-up and 22 (8.2%) were withdrawn 
from the study while on TB treatment before completing 
week 24. The reasons for withdrawal include: ART failure 
(two) necessitating switch to second-line ART, pregnancy 
(one), renal failure (three), liver toxicity necessitating 
interruption in TB treatment (five), drug resistant strains 
of TB (eight), TB meningitis (one), efavirenz toxicity 
necessitating switch to nevirapine (one), based on the 
medical judgement of the clinician (one). Of the 203 
(75.7%) patients who completed TB treatment and are 
now in the routine follow-up phase for 5 years, 3 (1.1%) 
died, 10 (3.7%) were transferred, 7 (2.6%) were lost to 
follow-up and 1 (0.4%) was withdrawn from the study.
tb diagnosis
Table 4 presents the results of the TB diagnostic tests 
of the patients enrolled in the study: 249 (92.9%) had 
a diagnosis of TB confirmed by sputum microscopy, 
Xpert or culture (microbiologically confirmed TB); 215 
(80.2%) patients were culture positive and of those who 
were culture negative, 10 (3.7%) were Xpert/RIF positive 
and 13 (4.9%) was smear positive. Eleven (4.1%) patients 
had contaminated culture results and were diagnosed 
by a positive smear 7 (2.6%) and Xpert/RIF 4 (1.5%) 
only. Nineteen (7.1%) patients were clinically diagnosed. 
Xpert/RIF was performed in 138/268 patients of whom 
126 were positive. Patients were categorised as sputum 
smear positive if the sputum microscopy results were posi-
tive at baseline or week 2.
Planned substudies
This population of patients will be followed up for a 
period of 5 years. The SOUTH cohort has been estab-
lished with the aim of providing an ideal research plat-
form for additional study questions and for fostering new 
collaborations.
During the course of the study a number of substudies 
have been planned and are under implementation, 
including:
1. Efavirenz concentration measurement. This study 
will be conducted on stored samples with the aim 
of describing the serum levels of efavirenz taken 
with concomitant anti-TB drugs and evaluating the 
association with toxicity
2. Viral load test: since routine viral load monitoring 
had not been implemented at the time of the set-up 
of the study, viral load measurement will be measured 
on stored samples to evaluate the proportion of pa-
tients with detectable viral load after 6 months of ART. 
Patients with a detectable viral load will be referred to 
the clinician-in-charge for counselling and evaluation 
for a switch to second-line ART.
3. Radiological evaluation study: we will perform eval-
uation of all chest X-rays and correlate radiological 
group.bmj.com on December 5, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Sekaggya-Wiltshire C, et al. BMJ Open 2017;7:e014679. doi:10.1136/bmjopen-2016-014679
Open Access
Table 3 Patients’ characteristics at cohort enrolment
Characteristics N=268
Gender, males, n (%) 157 (58.6)
Age, years (median, IQR) 34 (29–40)
Months from HIV to TB diagnosis, 
median (CI)
2 (0 to 22.5)
BMI
  Median (CI), kg/m2) 19.2 (IQR 17.7–21.7)
  <18 76 (28.4%)
CD4 count 
  Median (CI), cells/µL 163 (46 to 298)
  <200 cells/µL, n (%) 149 (57.5)
  <50 cells/µL, n (%) 66 (25.5)
ART
  Naive, n (%) 202 (75.4)
  First line, n (%) 63 (23.5)
  Second line, n (%) 3 (1.1)
Symptoms, n (%)
  Cough for at least 2 weeks 258 (97.0)
  Fever 225 (84.6)
  Night sweats 208 (78.2)
  Weight loss 244 (91.7)
History of liver disease, n (%) 1 (0.4)
History of kidney disease, n (%) 1 (0.4)
Herbal use, n (%) 61 (22.8)
Smoking history, n (%) 19 (7.1)
Alcohol consumption, n (%) 35 (13.1)
ART, antiretroviral therapy; BMI, body mass index; TB, 
tuberculosis.
Table 4 Results of the tuberculosis diagnostic tests of the 
patients enrolled in the study
Test description
n (%)
Culture+ Culture−
Smear+ 175 (65.3) 14 (5.2)
Smear− 40 (14.9) 27 (10.1)
+, positive; −, negative.
changes with anti-TB drug concentrations and TB 
treatment outcome.
4. Intensive pharmacokinetic study: we will carry out in-
tense pharmacokinetic analysis at more time points in 
a subset of patients to describe their exposure to the 
anti-TB drugs over a 24-hour period.
5. Pharmacogenetic analysis: in collaboration with the 
University of Turin (Italy) a laboratory technician has 
been trained to carry out pharmacogenetic analysis 
on the stored blood samples. We will be able to 
correlate serum drug concentrations and outcome 
while taking into consideration the genetic variability 
of our population.
FIndIngs to dAte
In this paper, we have documented the set-up of a large, 
well-characterised cohort of adults coinfected with TB/
HIV with multiple datasets; detailed clinical, microbio-
logical, radiological and pharmacokinetic information 
provides a resourceful platform for undertaking current 
and future studies in this population. It is also one of the 
largest pharmacokinetic datasets collected prospectively 
among patients coinfected with TB/HIV.
The majority of patients in this cohort had severe 
immunosuppression with a CD4 cell count of <200 cells/
µL and about a quarter of them had a CD4 cell count 
less than 50 cells/µL. This population is consistent with 
those most at risk of TB infection. Furthermore, over 
75% of the patients were ART naive when diagnosed with 
new pulmonary TB demonstrating the late presentation 
and initiation of ART in this population. Whether only 
patient factors led to late presentation or a limitation in 
access to specialised HIV care in this resource-limited 
setting contributed to the late initiation of ART remains 
unknown.
Despite the well-known challenges clinicians are faced 
with when diagnosing TB, especially in patients with HIV 
infection, we achieved microbiological confirmation of 
TB in 90% of our patients. This was possible by using 
several methods including sputum microscopy, culture 
and Xpert MTB/RIF. In the routine clinical setting in a 
resource-limited country this is not always possible and 
TB is therefore often time diagnosed clinically.17
The mortality rate among this cohort of patients while 
on TB treatment (6.3%) is similar to that reported coun-
trywide mortality (6.4%),18 regardless of the controlled 
environment in the study setting. On the other hand, 
and as expected in a study setting, the loss to follow-up 
rate during TB treatment is much lower (3%) than in 
our routine clinical setting (10%)11 due to the delib-
erate attempts made to track patients and ascertain their 
outcome.
The main objective of this study is to determine the 
association between anti-TB drug concentrations and 
treatment outcomes. There are several factors that may 
affect anti-TB drug concentrations, for example, poor 
adherence, male sex and low BMI have been associated 
with low anti-TB drug concentrations. Drug–drug inter-
actions may also lead to variation in anti-TB drug concen-
trations, for example, McIlleron et al reported a transient 
increase in pyrazinamide and ethambutol concentrations 
in the first few weeks following ART initiation which may 
contribute to hepatotoxicity while a decrease in rifam-
picin concentrations was observed. These, however, were 
not statistically significant.4 Rifampicin, due to its CYP450 
enzyme induction effect leads to a decrease in concentra-
tions of the most commonly used non-nucleoside reverse 
transcriptase inhibitors (nevirapine and efavirenz).
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Patients with HIV infection have been found to have 
low anti-TB concentrations due to malabsorption.5 
Several authors have found that low anti-TB drug concen-
trations (pyrazinamide, rifampicin and isoniazid) were 
associated with poor TB treatment outcomes7 13 19 20 
while others did not.8 21 22 Many of these studies were 
retrospective with small sample sizes and only a few 
included patients with HIV infection. This is an aspect 
that this study will explore further and contribute to 
the existing studies by providing prospectively collected 
data with a considerably large sample size including 
a population of severely immunosuppressed patients 
coinfected with TB/HIV who at a particularly high 
risk of poor TB treatment outcomes. Aside from drug 
concentrations, we will be able to explore how other 
factors that may affect TB treatment outcomes in our 
population including low CD4 cell count, bacillary load 
and bilateral radiological disease.
TB is a known driver of HIV progression and vice 
versa; while patients with HIV have more severe 
presentations of TB and worse TB treatment outcomes 
(including death) compared with those without HIV, 
TB leads to increased transcriptional activity of HIV 
virus and therefore progression of HIV disease.23 The 
SOUTH cohort is a unique asset to determine long-
term outcomes of patients coinfected, and to answer 
relevant clinical questions on HIV-positive patients with 
a diagnosis of TB. Because TB may serve as a marker 
of severe immunosuppression, patients with a history 
of TB have decreased long-term survival and a higher 
incidence of new AIDS-defining opportunistic infec-
tions compared with those with no history of TB.24 25 
This study population of severely immunosuppressed 
patients will enable us to characterise these long-term 
outcomes further.
We have described the assembling of a large, well-char-
acterised TB/HIV coinfection cohort with multiple 
datasets including pharmacokinetics. This cohort will 
facilitate our group’s contribution to the characterisa-
tion of the association between TB treatment outcomes 
and serum drug concentrations of first-line anti-TB 
medications. Furthermore, it provides an excellent 
platform for a variety of planned substudies including 
pharmacogenetics.
strengths And lIMItAtIons
The strength of this cohort lies in its relatively large 
sample size. In addition, pharmacokinetic data are 
collected prospectively and at three time points and on 
three different occasions which enables us to estimate the 
maximum concentrations better.
The limitation of this study is that directly observed 
therapy is only performed on the study visit and not 
throughout the course of TB treatment. Adherence 
to treatment between study visits relies may affect drug 
concentrations; however, data on adherence is collected.
collAborAtIon
Data from this cohort will be available on reasonable 
request and with permission of Infectious Diseases and 
UZH collaboration. Collaboration with other researchers 
with interest in pharmacokinetic research in patients 
coinfected with TB/HIV is encouraged and can be sought 
through the Infectious Diseases—UZH collaboration.
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